Physician profile
Nathan David Zasler
NPI 1457656969
$1,371.09
in general payments reported to CMS, 2019-2025
29 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Neuromuscular Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $128).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $94.16 · 2021: $144 · 2022: $164 · 2023: $144 · 2024: $358 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.24 | 2021-2025 | Ubrelvy, Qulipta |
| Lundbeck LLC | $154.03 | 2020-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $134.75 | 2019-2025 | Nuedexta, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.54 | 2024-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $80.53 | 2020-2022 | |
| Merz North America, INC. | $76.13 | 2019 | |
| Pfizer INC. | $58.89 | 2023-2025 | |
| Lilly USA, LLC | $52.74 | 2021 | |
| Supernus Pharmaceuticals, INC. | $42.97 | 2024 | Qelbree |
| Azurity Pharmaceuticals, INC. | $41.73 | 2024-2025 | Horizant |
| Axsome Therapeutics, INC. | $41.07 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $37.29 | 2023-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $36.34 | 2025 | Austedo Xr, Ajovy |
| Dompe US, INC. | $33.06 | 2022-2025 | Oxervate |
| Neurocrine Biosciences, INC. | $32.27 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $26.99 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $24.90 | 2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $20.49 | 2019 | |
| Ucb, INC. | $20.38 | 2020 | |
| Vanda Pharmaceuticals INC. | $19.03 | 2025 | Fanapt |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2024 | Trintellix |
| Harrow Eye, LLC | $17.51 | 2025 | Vevye |
| Collegium Pharmaceutical, INC. | $15.54 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $14.88 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.79 | 2021 | |
| Eisai INC. | $14.24 | 2024 | |
| Merck Sharp & Dohme LLC | $11.92 | 2022 | |
| Amgen INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Zasler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.